Childress Capital Advisors LLC Increases Stake in Merck & Co., Inc. $MRK

Key Points

• Childress Capital Advisors boosted its stake in Merck by 71.7%, buying an additional 9,529 shares to hold 22,819 shares worth $2.402 million at quarter end.
• Merck posted an EPS beat for the quarter ($2.04 vs. $2.01) with revenue of $16.40 billion (+5% YoY), set FY2026 EPS guidance of 5.000–5.150, and trades with a consensus analyst rating of "Moderate Buy" and a $128.47 target amid several price‑target increases.
• Company insiders have been net sellers recently: CEO Robert M. Davis sold 47,434 shares (a 9.66% reduction in his holding), and insiders disposed of 320,176 shares worth about $38.3 million over the past 90 days.

Childress Capital Advisors LLC boosted its stake in Merck & Co., Inc. (NYSE:MRK - Free Report) by 71.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 22,819 shares of the company's stock after purchasing an additional 9,529 shares during the period. Childress Capital Advisors LLC's holdings in Merck & Co., Inc. were worth $2,402,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the stock. Westside Investment Management Inc. increased its stake in Merck & Co., Inc. by 3.1% in the 4th quarter. Westside Investment Management Inc. now owns 3,142 shares of the company's stock worth $331,000 after purchasing an additional 93 shares during the period. Payne Capital LLC increased its stake in Merck & Co., Inc. by 0.9% in the 4th quarter. Payne Capital LLC now owns 10,637 shares of the company's stock worth $1,120,000 after purchasing an additional 97 shares during the period. Abound Wealth Management increased its stake in Merck & Co., Inc. by 6.8% in the 4th quarter. Abound Wealth Management now owns 1,554 shares of the company's stock worth $164,000 after purchasing an additional 99 shares during the period. Mattern Wealth Management LLC increased its stake in Merck & Co., Inc. by 1.7% in the 4th quarter. Mattern Wealth Management LLC now owns 6,033 shares of the company's stock worth $635,000 after purchasing an additional 100 shares during the period. Finally, Jmac Enterprises LLC increased its stake in Merck & Co., Inc. by 1.6% in the 4th quarter. Jmac Enterprises LLC now owns 6,616 shares of the company's stock worth $696,000 after purchasing an additional 103 shares during the period. 76.07% of the stock is owned by hedge funds and other institutional investors.

Merck & Co., Inc. Price Performance

MRK opened at $118.07 on Thursday. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.30 and a current ratio of 1.54. Merck & Co., Inc. has a 52-week low of $73.31 and a 52-week high of $125.14. The stock has a market capitalization of $291.62 billion, a PE ratio of 16.22, a price-to-earnings-growth ratio of 2.41 and a beta of 0.26. The stock's 50 day moving average price is $119.26 and its 200-day moving average price is $105.51.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its earnings results on Tuesday, February 3rd. The company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.01 by $0.03. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.The firm had revenue of $16.40 billion for the quarter, compared to analysts' expectations of $16.19 billion. During the same period in the previous year, the firm earned $1.72 earnings per share. The business's revenue was up 5.0% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. On average, equities research analysts predict that Merck & Co., Inc. will post 9.01 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, April 7th. Stockholders of record on Monday, March 16th were paid a dividend of $0.85 per share. The ex-dividend date of this dividend was Monday, March 16th. This represents a $3.40 annualized dividend and a dividend yield of 2.9%. Merck & Co., Inc.'s payout ratio is 46.70%.

Insider Activity

In related news, CEO Robert M. Davis sold 47,434 shares of Merck & Co., Inc. stock in a transaction that occurred on Wednesday, February 4th. The stock was sold at an average price of $118.04, for a total transaction of $5,599,109.36. Following the sale, the chief executive officer directly owned 443,602 shares in the company, valued at $52,362,780.08. The trade was a 9.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CMO Chirfi Guindo sold 20,000 shares of Merck & Co., Inc. stock in a transaction that occurred on Thursday, February 5th. The shares were sold at an average price of $121.88, for a total value of $2,437,600.00. Following the sale, the chief marketing officer owned 80,615 shares in the company, valued at $9,825,356.20. This represents a 19.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 320,176 shares of company stock valued at $38,281,735. 0.13% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

MRK has been the topic of a number of analyst reports. Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $142.00 price target on shares of Merck & Co., Inc. in a research note on Monday, March 30th. Guggenheim lifted their price target on Merck & Co., Inc. from $122.00 to $140.00 and gave the stock a "buy" rating in a research note on Friday, February 6th. Citigroup lifted their price target on Merck & Co., Inc. from $120.00 to $125.00 and gave the stock a "neutral" rating in a research note on Friday, March 20th. UBS Group lifted their price target on Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a "buy" rating in a research note on Monday. Finally, Wells Fargo & Company boosted their target price on Merck & Co., Inc. from $135.00 to $150.00 and gave the company an "overweight" rating in a research note on Thursday, March 12th. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and seven have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $128.47.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: FDA grants priority review to Merck and Daiichi’s BLA for ifinatamab deruxtecan in extensive-stage small cell lung cancer — this accelerates the regulatory timeline for a potentially material oncology asset and could add to future revenue if approved. MRK, Daiichi's BLA for ADC Drug Gets FDA Priority Tag in Lung Cancer
• Positive Sentiment: UBS raised its price target on MRK to $145, signaling bullish analyst sentiment and providing support for longer‑term upside relative to current levels. UBS Group Boosts Merck & Co., Inc. NYSE: MRK Price Target to $145.00
• Positive Sentiment: Keytruda remains the primary growth driver (over half of pharma sales); analysts will be watching Q1 results and guidance for continued uptake from new indications — a clean print would likely stabilize the stock. Will Keytruda Continue to Aid Merck's Top Line in Q1 Earnings?
• Neutral Sentiment: Options/technical coverage: a retail/options piece outlines a bullish diagonal trade targeting $130 by mid‑June — this reflects trader optimism but is speculative and not company‑fundamental. This Merck (MRK) stock bullish diagonal trade targets a price of $130 by June 18
• Neutral Sentiment: Industry tailwinds in animal health highlighted in a market report (Merck’s animal-health unit participates in this market), a long‑term positive structural theme but not an immediate catalyst. Animal Health Market Intelligence Report 2026-2034
• Neutral Sentiment: Coverage about Merck KGaA XTRA: MRK appears in the news stream — note this is a different company (German Merck), which can cause ticker confusion among retail investors but does not affect Merck & Co.’s fundamentals. Assessing Merck KGaA XTRA: MRK Valuation After Mixed Recent Share Performance And Healthcare Pipeline Developments
• Negative Sentiment: Media scrutiny of Merck’s patent strategies and pricing for Keytruda (USAToday feature) can increase regulatory and reputational risk; that scrutiny can weigh on sentiment and prompt selling or political/regulatory pressure. How Merck keeps prices for its blockbuster cancer drug sky high
• Negative Sentiment: Near‑term price weakness / market reaction: recent intraday moves show MRK underperforming broader indices, reflecting profit‑taking and caution ahead of earnings/updates. Merck (MRK) Stock Sinks As Market Gains: Here's Why

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.